Cronos Group Chief Innovation Officer Dr. Todd Abraham to Retire

2 years ago

Arye Weigensberg Named Interim Head of Research and Development Search to Identify Permanent Successor Well Underway TORONTO, Oct. 29, 2021…

Jushi Holdings Inc. to Open its 26th Store Nationwide and 2nd BEYOND / HELLO™ Retail Location in Virginia

2 years ago

BEYOND / HELLO™ Sterling to Open On Tuesday, November 2nd at 10:00 a.m., BEYOND / HELLO™ Sterling will begin serving…

Mydecine to Participate in Wonderland: Miami on November 8-9, 2021

2 years ago

DENVER, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’),…

Rapid Micro Biosystems to Present at Stifel 2021 Virtual Healthcare Conference

2 years ago

LOWELL, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an…

Cytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference

2 years ago

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data relating…

Cerner Reports Third Quarter 2021 Results

2 years ago

Delivers Strong Results Across Key MetricsGAAP Operating Margin and Diluted EPS Lower; Adjusted Operating Margin and Adjusted Diluted EPS Both…

HEXO Reports Fourth Quarter and Fiscal Year 2021 Financial Results Highlighting Strong Growth

2 years ago

Total net sales growth of 71% quarter-over-quarter and 43% from Q4’20, marking HEXO's best quarter of sales to date.Total Q4’21…

IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results

2 years ago

Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23Increases full-year…

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

2 years ago

Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function Webinar to be held Friday, Nov.…

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction

2 years ago

FREEDOM-2 trial will evaluate the potential for the company’s investigational allogeneic cell therapy, FCR001, to induce durable immune tolerance in…